Ocugen, Inc. Broadcasts Dosing Of completion of Topics with Stargardt in Cohort 1 of Section 1/2 Scientific Trial Comparing the Protection and Efficacy of OCU410ST
OcugenMALVERN, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Corporate”) (NASDAQ: OCGN), a biotechnology corporate concerned about finding, creating, and commercializing novel gene and cellular treatments and vaccines,